Italy Insulin Delivery Devices Market Overview, 2031

Italy has a high prevalence of diabetes, necessitating a healthy market for insulin delivery devices. As of the prevalence of both type 1 and type 2 diabetes, there is a high demand for efficient and diversified insulin administration options. Italy has demonstrated a strong proclivity for implementing breakthrough healthcare technologies. This trend is also evident in insulin delivery devices, where there is a growing interest in cutting-edge technologies such as closed-loop systems artificial pancreas and hybrid closed-loop insulin delivery systems. These cutting-edge technologies are designed to enable more automatic and precise insulin delivery, hence improving glycemic control. Telemedicine and remote monitoring are important components of the Italian healthcare scene, particularly diabetes management. Insulin delivery systems that offer remote monitoring or communication with telemedicine platforms allow healthcare practitioners to assess patient data and provide timely interventions or adjustments in treatment plans. The insulin delivery device industry is influenced by Italy's developing healthcare reforms and public health efforts. The country is still looking into ways to improve diabetes care, including increasing access to advanced devices, funding research, and promoting collaborations for improved patient results. With an ageing population, Italy is facing demographic upheavals. As diabetes prevalence rises with age, there is an increasing demand for effective diabetes management options, such as insulin delivery devices, to meet the unique demands of older people. In Italy, efforts are being made to connect healthcare systems and increase interoperability between devices and electronic health records EHRs. Insulin delivery devices that interact smoothly with existing healthcare infrastructure and EHR systems are recognised for their capacity to simplify data sharing and improve the continuity of treatment.

According to the research report, " Italy Insulin Delivery Devices Market Overview, 2031," published by Bonafide Research, the Italy Insulin Delivery Devices market was valued at more than USD 747.96 Million in 2025. Italy has made investments in diabetes prevention and early intervention programmes. The insulin delivery devices primarily serve people who have been diagnosed with diabetes, the country is increasingly emphasising prevention and early diagnosis. This strategy attempts to minimise the total diabetes burden, potentially influencing the long-term need for insulin delivery devices. Collaborations between pharmaceutical companies and insulin delivery device makers are common in Italy. These collaborations frequently focus on developing unique insulin formulations that are compatible with certain device technology, with the goal of improving patient efficacy, stability, and convenience of delivery. Precision medicine is becoming more important in Italy's healthcare sector. In diabetes care, this translates into personalised treatment strategies that take into account unique patient characteristics. Insulin delivery systems contribute to this trend by providing customised features that suit patient’s specific needs and preferences. Diabetes awareness and activism are becoming more prominent in Italy. Patient advocacy groups and organisations seek to improve awareness, decrease stigma, and encourage access to appropriate diabetes management technologies, such as insulin delivery devices, while also campaigning for greater resources and support for individuals living with diabetes. Italy adheres to recognised clinical recommendations and best practices for diabetes management. These guidelines frequently propose insulin therapy as a critical component for glycemic control in specific patient populations, influencing the use and uptake of insulin delivery devices.

Italy insulin delivery devices market by product types is divided into insulin pens, insulin pump, insulin syringes and other insulin delivery services. In Italy, the market for insulin delivery devices is divided into categories based on product types, including insulin pens, insulin pumps, insulin syringes, and other delivery solutions like smart devices and patch pumps. Insulin pens are the leading and most recognized category, mainly due to their convenience for self-injection, precise dosing, and high familiarity among patients. Both reusable and disposable pens are commonly used, with reusable versions capturing a large part of the market due to their cost-efficiency and environmental advantages for users over time. This segment is projected to grow steadily as diabetes cases rise and there’s an increasing recommendation from healthcare providers for pen devices in standard treatments. Insulin pumps, such as tethered systems and patch pumps, are among the swiftly expanding segments in Italy. These devices provide continuous insulin delivery under the skin and are becoming the preferred option for Type 1 diabetes patients who need tighter blood sugar control and fewer injections. The patch pump segment, in particular, is expected to grow significantly with double-digit compound annual growth rate expectations. At the same time, traditional insulin syringes are still important, especially in cases where budget or access issues limit the use of pens or pumps. New other delivery technologies including smart devices that connect to digital health systems and innovative patch designs are becoming more popular with tech-savvy patients and specialized diabetes clinics. A variety of products and the adoption of new technologies are changing the landscape of insulin devices in Italy, with pens leading in usage and pumps contributing to market growth.

Italy insulin delivery devices market by disease types is divided into type 1 and type 2. The landscape of insulin delivery devices in Italy is also influenced by the types of diabetes, mainly Type 1 and Type 2, which have distinct medical requirements and affect device demand. Epidemiological statistics reveal that about 10% of Italians with diabetes have Type 1, while nearly 90% have Type 2, mirroring broader patterns in Western Europe. Type 1 individuals usually need lifelong insulin treatment from the moment they are diagnosed, which has driven the adoption of advanced delivery systems such as insulin pumps and continuous infusion methods. Pumps are especially appealing in this group because they offer more natural insulin delivery and can integrate with glucose monitoring systems to enhance glucose management. For the larger Type 2 group, insulin pens and syringes are the main delivery methods due to their adequacy for on-and-off insulin schedules and the simplicity that patients prefer. The widespread use of pens in this segment is associated with their ease of handling and availability through the Italian National Health Service, which funds essential care for qualifying patients. As awareness of diabetes and the importance of early treatment grow across Italy, the demand for a variety of delivery devices continues to rise, influenced by the severity of the disease, doctor prescribing patterns, and patient choices.

Italy insulin delivery devices market by end user is divided into home care setting, hospitals and clinics and other end users. Segmentation by end user in the market for insulin delivery devices in Italy comprises home care, hospitals and clinics, as well as other specialized care settings like long-term care institutions and diabetes centers. Home care continues to be the leading sector, reflecting the chronic and ongoing nature of diabetes management that enables patients to self-administer insulin outside of healthcare facilities. Insulin pens and increasingly popular wearable pumps are crucial for at-home care as they promote independence, lessen reliance on healthcare providers, and integrate seamlessly into daily life. The Italian National Health Service enhances this trend by improving access to devices and offering training, which allows patients to effectively handle their therapy at home. Hospitals and clinics remain essential for initial diagnosis, during acute episodes, and for educating patients as well as providing device training. Clinical environments are also where more sophisticated delivery technologies, such as advanced pumping systems and hybrid closed-loop devices, are introduced and initial adjustments are made under professional guidance. Other end users, such as specialized diabetes centers and long-term care facilities, also play a role in device usage, especially for patients needing ongoing clinical assistance or those with multiple health issues. By coordinating care across these different end-user categories, the Italian market fosters a comprehensive approach to diabetes management that aligns device choices with patient requirements, care complexity, and the healthcare system.



"Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031
Aspects covered in this report
• Insulin Delivery Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By product Types
• Insulin Pens
• Insulin Pump
• Insulin Syringes
• Others Insulin Delivery Devices

By Disease Types
• Type 1
• Type 2

By End User
• Home care setting
• Hospitals & clinics
• Others End users “